Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.75 |
| ▸ | ARG1 | P05089 | 5/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.42 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.39 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.39 |
| ▸ | ARG2 | P78540 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL730489 | 1.00 | MEN1 (1.00) | MEN1BLMKMT2ASLC1A2ARG1 | |
| SCHEMBL730490 | 1.00 | MEN1 (1.00) | MEN1BLMKMT2ASLC1A2ARG1 | |
| SCHEMBL7354481 | 1.00 | MEN1 (1.00) | MEN1BLMKMT2ASLC1A2ARG1 | |
| SCHEMBL6342928 | 1.00 | MEN1 (1.00) | MEN1BLMKMT2ASLC1A2ARG1 | |
| SCHEMBL6342925 | 1.00 | MEN1 (1.00) | MEN1BLMKMT2ASLC1A2ARG1 | |
| SCHEMBL28347967 | 0.98 | MEN1 (0.96) | MEN1BLMKMT2ASLC1A2ARG1 | |
| SCHEMBL28348164 | 0.98 | MEN1 (0.96) | MEN1BLMKMT2ASLC1A2ARG1 | |
| SCHEMBL17743431 | 0.98 | MEN1 (0.96) | MEN1BLMKMT2ASLC1A2ARG1 | |
| SCHEMBL3463284 | 0.86 | SLC1A2 (1.00) | MEN1BLMKMT2ASLC1A2ARG1 | |
| SCHEMBL2177035 | 0.86 | SLC1A2 (1.00) | MEN1BLMKMT2ASLC1A2ARG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3668524-A1 | TARGETING 2 -1-BOUND GLUTAMATE RECEPTORS FOR TREATING DISEASES AND DISORDERS | Board Of Regents, The University Of Texas System (US) | 2020-06-24 | — | — | EP | claimed |
| US-20200181201-A1 | TARGETING ALPHA2DELTA-1-BOUND GLUTAMATE RECEPTORS FOR TREATING DISEASES AND DISORDERS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-06-11 | — | — | US | claimed |
| WO-2019036511-A1 | TARGETING α2δ-1-BOUND GLUTAMATE RECEPTORS FOR TREATING DISEASES AND DISORDERS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-02-21 | — | — | WO | claimed |
| WO-2015127558-A1 | METHODS AND USES FOR INDUCING OR FACILITATING MICTURITION IN A PATIENT IN NEED THEREOF | UNIVERSITé LAVAL (CA) | 2015-09-03 | — | — | WO | claimed |
| US-20110137036-A1 | SYNTHESIS OF (4aS,7aS)-OCTAHYDRO-1H-PYRROLO[3,4-b]PYRIDINE | F.I.S. FABBRICA ITALIANA SINTETICI S.P.A (IT) | 2011-06-09 | — | — | US | claimed |
| US-12180251-B2 | Nucleic acids encoding peptides that block binding of a2d-1 to glutamate receptors for treating diseases and disorders | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-12-31 | — | — | US | disclosed |
| US-20240409514-A1 | METHODS FOR INHIBITING NATIVE AND PROMISCUOUS UPTAKE OF MONOAMINE NEUROTRANSMITTERS | ETHISMOS RESEARCH, INC. (US) | 2024-12-12 | — | — | US | disclosed |
| US-20240300931-A1 | Composition and Methods for Treating Attention Deficit Disorders | LIPPA ARNOLD STAN (US) | 2024-09-12 | — | — | US | disclosed |
| US-12042481-B2 | Use of (1R,5S)-(+)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters | OTSUKA AMERICA PHARMACEUTICAL, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240083951-A1 | TARGETING ALPHA2DELTA-1-BOUND GLUTAMATE RECEPTORS FOR TREATING DISEASES AND DISORDERS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-03-14 | — | — | US | disclosed |
| US-20230373982-A1 | Compositions And Methods For Treating Attention Deficit Disorders | LIPPA ARNOLD STAN (US) | 2023-11-23 | — | — | US | disclosed |
| US-11787839-B2 | Targeting α2δ-1-bound glutamate receptors for treating diseases and disorders | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-10-17 | — | — | US | disclosed |
| EP-0457324-A1 | Heterocyclic-NMDA antagonists | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-11-21 | — | — | EP | disclosed |
| US-5064657-A | Spider toxins and methods for their use as blockers of amino acid receptor function | UNIVERSITY OF UTAH (US) | 1991-11-12 | — | — | US | disclosed |
| WO-1991006648-A1 | GLUTAMATE RECEPTOR COMPOSITIONS AND METHODS | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1991-05-16 | — | — | WO | disclosed |
| WO-1991002523-A1 | GLUTAMATERGIC AMINO ACID AGONISTS AND ANTAGONISTS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1991-03-07 | — | — | WO | disclosed |
| US-4990504-A | Modulate excitatory amino acid receptor system | FIDIA-GEORGETOWN INSTITUTE FOR THE NEUROSCIENCES (US) | 1991-02-05 | — | — | US | disclosed |
| US-4946839-A | ALZHEIMER'S DISEASE | FIDIA-GEORGETOWN INSTITUTE FOR THE NEUROSCIENCES (US) | 1990-08-07 | — | — | US | disclosed |
| US-4925664-A | Spider toxins and methods for their use as blockers of calcium channels and amino acid receptor function | UNIVERSITY OF UTAH (US) | 1990-05-15 | — | — | US | disclosed |
| EP-0299513-A1 | Azetidine derivatives, compositions and their use | FIDIA-GEORGETOWN INSTITUTE FOR THE NEUROSCIENCES (US) | 1989-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12042481-B2 | Use of (1R,5S)-(+)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters | HTR5A, CHRNA5, HTR1A | MEN1 3100/4885BLM 3548/4885KMT2A 1891/4885 |
| US-20240409514-A1 | METHODS FOR INHIBITING NATIVE AND PROMISCUOUS UPTAKE OF MONOAMINE NEUROTRANSMITTERS | SLC18A2, SLC6A2, SLC18A3 | MEN1 2473/4885BLM 4108/4885KMT2A 2302/4885 |
| US-20110137036-A1 | SYNTHESIS OF (4aS,7aS)-OCTAHYDRO-1H-PYRROLO[3,4-b]PYRIDINE | PDXK, OXA1L, PDK4 | MEN1 4493/4885BLM 2299/4885KMT2A 4545/4885 |
| US-20230373982-A1 | Compositions And Methods For Treating Attention Deficit Disorders | GRIN2A, GRIN2C, GRM2 | MEN1 4826/4885BLM 2798/4885KMT2A 1530/4885 |
| US-20240300931-A1 | Composition and Methods for Treating Attention Deficit Disorders | GRIN2A, GRIN2C, NTRK2 | MEN1 4824/4885BLM 2853/4885KMT2A 1678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.